Karez Namiq

Medical Oncologist, Iraq

Title: Neoadjuvant Therapy in Nonmetastatic Breast Cancer in Kurdistan, Iraq

Abstract

Background: Breast cancer is the most common cancer in women. Locally advanced breast cancer (LABC) is defined as inoperable breast adenocarcinoma without distant metastases. Patients with LABC require a multidisciplinary approach. Its core management includes surgical removal of the tumor either by breast conserving surgery (BCS) or mastectomy, and there is a great variability in surgical practice for treating that cancer in different countries. Neoadjuvant chemotherapy has been the standard treatment for locally advanced breast cancer for the purpose of downstaging or for conversion from mastectomy to BCS.

Purpose: This study aimed to assess the treatment approach for nonmetastatic breast cancer in the Kurdistan region of Iraq and to compare its alignment with the current international recommendations for cancer treatment.

Patients and Methods: We retrospectively reviewed the records of 1000 eligible patients who underwent either breast-conserving surgery or mastectomy for non-metastatic invasive breast cancer at oncology centers located in the Kurdistan region of Iraq between the period 2016– 2021.

Results: Out Of 1000 patients (median age, 47 years (range, 22–85 years)), 60.2% underwent a mastectomy and 39.8% underwent breast conserving surgery. The proportion of patients treated with neoadjuvant chemotherapy has increased over time, with 8.3% of patients receiving neoadjuvant treatment in 2016 compared to 14.2% in 2021. Similarly, breast-conserving surgery has risen from 36.3% in 2016 to 43.7% in 2021. Most patients who underwent breast-conserving surgery had early breast cancer with a low nodal involvement burden.

Conclusion(s): The increasing trends of breast-conserving surgery practice in locally advanced breast cancer along with the increased use of neoadjuvant chemotherapy in the Kurdistan region in recent years comply with international guidelines. Our large multicenter, real-life series emphasizes the urgent need to implement and discuss more conservative surgical approaches, enhanced with the broader use of neoadjuvant chemotherapy, through education and information programs for health providers and patients, in the context of multidisciplinary team discussions, to deliver high-quality, patient centric breast cancer

Biography

Karez Namiq has completed her Medical Oncology MSc at the age of 35 years from Hawler Medical University, Erbil, Iraq. She has the European School of Oncology (ESO) Certificate of Competence in Breast Cancer - FOURTH COHORT (CCB4) as well as Certified Oncology Nutrition Consultant (ONC). Karez has over 10 publications.

4th International Conference on Oncology and Research Treatment

Karez Namiq

Title: Neoadjuvant Therapy in Nonmetastatic Breast Cancer in Kurdistan, Iraq

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at